title: Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
abstract: BACKGROUND
  The purpose of this retrospective population based study was to investigate the effect of the extent of surgery on overall survival in young versus adult glioblastoma patients in Vorarlberg/Austria during the last 4 years.
  
  
  METHODS
  Forty-eight patients (median age 62.5 years, ranging from 25-82 years, 19 female and 29 male) with histologically proven glioblastoma received surgery (16 biopsies, 18 partial and 14 complete resections) and postoperative chemo-irradiation with concomitant and adjuvant temozolomide. The median follow up of the patient population was 11.7 months (ranging from 3 to 36 months). Postoperative temporary morbidity was found in 5 out of 48 (10.4%) patients, and no mortality or permanent morbidity occurred. One infection led to revision surgery.
  
  
  RESULTS
  Altogether, the 12/24 months overall survival was 54/20.2% with a median survival of 13.7 months. In younger patients (<65 yrs, median 57.5 yrs, 28 patients), the 12/24 months overall survival was 68.4/34.3% with 16.9 months median survival, in the elderly patients (>65 yrs, median 73 yrs, 20 patients) the 12/24 months overall survival was 28.8/5.8%, with 7.7 months median survival (Log-rank, p = 0.0005). Extent of surgery influenced overall survival of the adult group nearly significantly (biopsy versus complete resection: p = 0.06), but did not affect overall survival of the elderly (p = 0.5).
  
  
  CONCLUSIONS
  Overall survival of elderly glioblastoma patients treated with surgery and chemo-irradiation with concomitant and adjuvant temozolomide is significantly reduced compared to the younger patients. In addition, in the elderly the extent of surgery did not influence the prognosis in our population.
authors: Department of Neurosurgery, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. iris.zachenhofer@lkhf.at
authors: Iris
authors: I
authors: Zachenhofer
authors: Roland
authors: R
authors: Maier
authors: Helmut
authors: H
authors: Eiter
authors: Martin
authors: M
authors: Muxel
authors: Bernhard
authors: B
authors: Muxel
authors: Manfred
authors: M
authors: Cejna
authors: Alexander
authors: A
authors: DeVries
authors: Karl
authors: K
authors: Roessler
references: Lancet Oncol. 2006 May;7(5):392-401
references: 16648043
references: Surg Neurol. 1998 Mar;49(3):282-8; discussion 288-9
references: 9508116
references: J Neurosurg. 2009 Jan;110(1):156-62
references: 18847342
references: J Neurooncol. 2011 Jul;103(3):611-8
references: 20953662
references: Anticancer Res. 2006 Sep-Oct;26(5B):3773-9
references: 17094400
references: Cancer Chemother Rep. 1966 Mar;50(3):163-70
references: 5910392
references: J Neurooncol. 2003 May;63(1):55-61
references: 12814255
references: Neuroepidemiology. 2009;33(1):17-22
references: 19325245
references: J Clin Oncol. 2008 May 1;26(13):2192-7
references: 18445844
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: J Neurol. 2003 May;250(5):561-8
references: 12736735
references: J Neurosurg. 2003 Sep;99(3):467-73
references: 12959431
references: Radiother Oncol. 2010 Dec;97(3):382-6
references: 20850883
references: J Clin Oncol. 2010 Apr 20;28(12):2051-7
references: 20308655
references: J Neurosurg. 2008 Apr;108(4):642-8
references: 18377240
references: Ann Surg Oncol. 2011 Jan;18(1):239-45
references: 20697823
references: J Neurol. 2009 May;256(5):734-41
references: 19240962
references: Stereotact Funct Neurosurg. 1997;68(1-4 Pt 1):33-8
references: 9711692
references: Cancer. 2009 Aug 15;115(16):3758-66
references: 19484785
references: J Neurosurg. 2010 Aug;113(2):325-32
references: 20302393
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: J Neurosurg. 2001 Aug;95(2):190-8
references: 11780887